#USA #Mequon #Microneedle Technology #Vector Science #peptide delivery

Vector Science and Therapeutics Introduces Groundbreaking Peptide-Matrix Microneedle Technology

In an exciting development, Vector Science and Therapeutics Corp. has unveiled its novel peptide-matrix microneedle technology, set to revolutionize the way therapeutic peptides are delivered. This innovative approach allows for non-invasive administration of these critical drugs through the skin, bypassing traditional hypodermic injections.

Overview of Peptide-Matrix Microneedle Technology

The new microneedle platform utilizes the therapeutic peptide as the needle's primary structural material. It aims to enhance drug delivery, particularly in the fields of sports medicine and regenerative medicine. By integrating the peptide into the microneedle itself, Vector is pioneering a method that promises both efficacy and convenience in treatment protocols.

Addressing Delivery Challenges

Delivering therapeutic peptides and large-molecule drugs presents significant hurdles, especially due to their size and the skin’s natural barrier. The outermost layer of skin, known as the stratum corneum, typically prevents meaningful penetration of such molecules, which complicates effective treatment options. Consequently, injections remain the primary method, leading to issues such as needle phobias and other practical inconveniences for patients.

A Revolutionary Approach

What sets Vector's microneedle apart is its unique design, which allows the peptide to act as the needle itself. These dissolvable microneedles are poised to pierce the outer skin layer and deliver a concentrated dose of peptides directly into the underlying tissues. As this delivery system aligns with patient comfort and care, healthcare providers may find the application less invasive and easier to manage in both clinical and self-care settings.

The additional design features include static patches and a handheld roller equipped with replaceable peptide-rich needle cartridges. This flexibility opens possibilities for a variety of medical applications, including regenerative medicine, wound care, dermatology, and targeted systemic therapies, which are currently under further investigation and validation.

Strategic Fit and Market Potential

Vector's innovation is not merely a standalone project; it's a core component of their intellectual property strategy, with 15 patent applications currently pending that encompass this state-of-the-art delivery method. With the global peptide therapeutics market projected to soar from approximately $140.9 billion in 2025 to about $294.6 billion by 2033, the possibilities for partnerships and expansion in peptide-based therapies are immense.

Tom Bachinski, Chief Technology Officer at Vector, stated, "Peptides represent some of the most promising therapeutics in both sports and regenerative medicine. We aim to change the standard of care in these fields by exploring new routes of administration like our microneedle technology. This platform could potentially revolutionize orthopedic treatments, much like how arthroscopy did decades earlier."

Moreover, Tommy Thompson, Chairman of Vector Science and Therapeutics, emphasized the importance of reducing invasiveness in treatment to enhance patient adherence and overall care. He noted that the company is committed to rigorous testing, focusing on safety and performance within the regulatory frameworks that govern medical innovation.

Development and Next Steps

Looking ahead, Vector aims to conduct comprehensive evaluations on aspects such as the mechanical strength of the needles, the stability of the peptides, their dissolution behavior, and overall delivery performance. While the technology holds much promise, it remains investigational and has not received approval from the FDA or relevant regulatory bodies. The firm acknowledges that the proof of safety and efficacy will be critical in determining its commercial viability.

About Vector Science and Therapeutics Corp.

Based in Mequon, Wisconsin, Vector Science and Therapeutics Corp. (TSXV: PAIN) is a leading medical technology firm dedicated to advancing drug delivery methods. The company specializes in producing cGMP-manufactured Rx peptides for applications in sports medicine, regenerative medicine, and pain management. Their commitment to rigorous standards ensures that these peptides are produced under conditions compliant with FDA and ISO regulations, making them suitable for physician use, unlike research-grade products that are restricted to research applications.

For further details on Vector Science and its innovative technologies, please visit Vector Science.